3.86
price up icon0.00%   0.00
after-market 시간 외 거래: 3.86
loading
전일 마감가:
$3.86
열려 있는:
$3.74
하루 거래량:
143.60K
Relative Volume:
1.35
시가총액:
$32.49M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-3.0394
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
-7.21%
1개월 성능:
-39.40%
6개월 성능:
-71.00%
1년 성능:
-80.65%
1일 변동 폭
Value
$3.512
$3.89
1주일 범위
Value
$3.51
$4.305
52주 변동 폭
Value
$3.51
$21.30

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
명칭
Karyopharm Therapeutics Inc
Name
전화
617-658-0600
Name
주소
85 WELLS AVENUE, NEWTON, MA
Name
직원
279
Name
트위터
@Karyopharm
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
KPTI's Discussions on Twitter

KPTI을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
3.86 32.49M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-01-19 개시 Piper Sandler Overweight
2022-11-04 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2022-02-09 업그레이드 JP Morgan Underweight → Neutral
2021-11-19 재개 Morgan Stanley Equal-Weight
2021-08-06 다운그레이드 JP Morgan Overweight → Neutral
2021-08-06 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-08-06 다운그레이드 SVB Leerink Outperform → Mkt Perform
2020-07-02 개시 Morgan Stanley Overweight
2020-03-04 개시 Barclays Overweight
2020-01-17 다운그레이드 Wedbush Outperform → Neutral
2019-07-23 업그레이드 JP Morgan Neutral → Overweight
2019-07-05 재확인 H.C. Wainwright Buy
2019-07-05 재확인 Robert W. Baird Outperform
2019-03-01 다운그레이드 JP Morgan Overweight → Neutral
2019-02-28 재확인 BofA/Merrill Underperform
2019-02-27 다운그레이드 BofA/Merrill Neutral → Underperform
2019-01-03 업그레이드 BofA/Merrill Underperform → Neutral
2018-12-03 개시 B. Riley FBR Buy
2018-11-09 업그레이드 Wedbush Neutral → Outperform
2018-05-24 다운그레이드 Wedbush Outperform → Neutral
2018-04-02 재개 Leerink Partners Outperform
2017-11-15 재개 H.C. Wainwright Buy
2017-09-15 개시 RBC Capital Mkts Outperform
2016-09-08 재확인 H.C. Wainwright Buy
2016-08-30 업그레이드 Jefferies Hold → Buy
2016-08-18 개시 H.C. Wainwright Buy
2016-06-28 개시 Robert W. Baird Outperform
모두보기

Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스

pulisher
Apr 02, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Apr 01, 2025
pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm Therapeutics Executives Sell Shares - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com

Mar 06, 2025
pulisher
Mar 06, 2025

Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India

Mar 06, 2025
pulisher
Mar 04, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM

Mar 03, 2025
pulisher
Mar 03, 2025

KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com

Mar 03, 2025
pulisher
Mar 02, 2025

Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat

Mar 02, 2025
pulisher
Mar 01, 2025

International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.

Mar 01, 2025
pulisher
Mar 01, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 25, 2025

Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Research Analysts Offer Predictions for KPTI Q1 Earnings - Defense World

Feb 24, 2025
pulisher
Feb 23, 2025

What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings? - The AM Reporter

Feb 23, 2025
pulisher
Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025
pulisher
Feb 21, 2025

HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025

Karyopharm Therapeutics Inc (KPTI) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
자본화:     |  볼륨(24시간):